The information below outlines details regarding GeneDx tests that will be discontinued effective March 04, 2024. We will continue to offer a robust genetic testing menu, and for a subset of the tests being discontinued, potential alternative tests have been identified to support you and your patients.
Below is a test comparison chart and timeline for when certain tests will be discontinued. Click here to view the FAQs regarding these test menu changes. For more information or to inquire about a test not listed below, please contact our client services team at support@genedx.com. GeneDx is proud to serve as your partner for genetic testing, services, and support.
Testing that has been discontinued and replacement options available:
| Discontinued Test | Replacement Test Option |
|---|---|
| XomeDx® Priority (TF37) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) Xpress options available for rapid results: XomeDxXpress® (896) |
| 65 Common mtDNA Variants and Deletion (704) | Mito Genome Sequencing and Deletion Testing (554) |
| Microcephaly Panel (689) | Microcephaly Xpanded Panel (J511) or XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Progressive External Ophthalmoplegia (PEO)/Optic Atrophy Nuclear Gene Panel (577) | Combined Mito Genome Plus Mito Focused Nuclear Gene Panel (615) |
| Abnormal Mineralization Panel (TA45) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Prenatal Targeted Chromosomal Microarray (410) | Prenatal Whole Genome Chromosomal Microarray (460) |
| Syndromic Macrocephaly/Overgrowth Panel (699) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Charcot-Marie-Tooth Panel (J778) | Hereditary Neuropathy Panel (737) |
| PTEN Gene Sequencing and Del/Dup (195) | PTEN is available on a variety of our Hereditary Cancer and Neurology panels including: Autism/ID panel (T395); Breast Cancer Management Panel (J055); Common Cancer Management Panel (B751); XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Comprehensive Hereditary Spastic Paraplegia Panel (941) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Hyperparathyroidism/Endocrine Tumor Panel (T828) | Oncogenedx custom panel (B749) |
| MECP2 Gene Sequencing & Del/Dup (549) | Comprehensive Epilepsy Panel (523), Rett/Angelman Syndrome Panel (729), or XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| TTR Gene Sequencing (363) | Hereditary Neuropathy Panel (737) Available on a variety of cardio panels including: Cardiomyopathy panel (694), Combined Cardiac Panel (935) |
| MitoXpanded Panel (J809) | XomeDx® Plus – Trio (561a & 561m) XomeDx® Plus – Duo (561e & 561m) XomeDx® Plus – Proband (561b & 561m) Or Combined Mito Genome Plus Mito Nuclear Panel (615) |
| Nystagmus Xpanded (J894) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Retinal Dystrophy Xpanded (J905) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| Cerebral Palsy Xpanded (T851) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
| XomeDx – Reflex after Xpanded (925) | XomeDx® – Trio (561a) XomeDx® – Duo (561e) XomeDx® – Proband (561b) |
To view complete list of available test options, visit the GeneDx test menu
Timeline of important dates regarding this change:
Last day to place a portal order: March 4, 2024 (Monday)
Last day to accept paper TRF order (accompanied by the sample): March 18, 2024 (Monday)
Last day to accept proband samples* (applicable to both portal and paper orders): March 18, 2024 (Monday)
*There will be a three-week grace period to send in biological parental samples to be included for trio tests.
All samples received after Monday, March 18, 2024, will be placed on hold, even if they correspond to orders received prior to that date. The GeneDx clinical team will reach out to discuss alternative test options.
All reports and results for tests received by March 18th will be communicated within our standard turnaround time. Please note, exceptions during benefit investigation and obtaining Prior Authorization can impact the turnaround time.
Please contact our customer service team at 888-729-1206 option 3 or support@genedx.com with any questions.
Thank you for trusting us as your testing partner.
Account
Contact